Expanded Access to Rovalpituzumab Tesirine
NCT03503890
·
clinicaltrials.gov ↗
NO_LONGER_AVAILABLE
Status
INDUSTRY
Sponsor class
Conditions
Small Cell Lung Cancer
Interventions
DRUG:
rovalpituzumab tesirine
Sponsor
AbbVie